Latest filing published 16 Dec 2021 for Greenwich LifeSciences, Inc., €4,884.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
David McWilliams: trading record in brief
David McWilliams, listed as board member, appears in our data through filings on Greenwich LifeSciences, Inc. shares, published by SEC (Form 4). Between 29 September 2020 and 14 December 2021, the trades on record add up to 7 filings.
Purchases make up the whole of the open-market record (3 purchases, €24k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 4 option exercises. So far in 2021, the count stands at 1 purchase and no sales.
The median purchase comes to €6,826. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.
The latest filing, published on 16 December 2021, reports an open-market purchase of €4,884 in Greenwich LifeSciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to David McWilliams
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 200 shares@ US$27.5609100.0% of flowCommon StockSEC:0001493152-21-031651:0Canonical exit: 14 Mar 2022 (T+90)
1 of 1 declaration
